艾拉莫德联合依那西普治疗难治性类风湿关节炎的疗效

Effect of Iguratimod with Etanercept in the Treatment of Refractory Rheumatoid Arthritis

目的探究艾拉莫德联合依那西普治疗难治性类风湿关节炎的疗效。方法选取2017年8月~2019年11月我院诊治的78例难治性类风湿关节炎患者,按随机数字表法分为对照组和观察组,各39例。对照组给予依那西普治疗,观察组给予在对照组基础上联合艾拉莫德治疗,比较两组临床疗效、类风湿因子(RF)、肿瘤坏死因子(TNF-α)、血管内皮生长因子(VEGF)水平和血清免疫球蛋白[免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)]。结果观察组治疗总有效率为94.87%,高于对照组的76.92%,差异有统计学意义(P<0.05);治疗后,观察组RF、TNF-α、VEGF、IgA、IgM、IgG低于对照组,差异有统计学意义(P<0.05)。结论艾拉莫德联合依那西普治疗可有效降低难治性类风湿关节炎患者炎症因子水平,改善免疫球蛋白,提高治疗效果。

Objective To investigate the efficacy of Iguratimod combined with etanercept in the treatment of refractory rheumatoid arthritis. Methods78 patients with refractory rheumatoid arthritis diagnosed and treated in our hospital from August 2017 to November 2019 were selected and divided into a control group and an observation group with a random number table method, 39 cases each. The control group was treated with etanercept, and the observation group was given combined with Iguratimod treatment based on the control group. The clinical efficacy, rheumatoid factor(RF), tumor necrosis factor(TNF-α), and vascular endothelial growth factor were compared(VEGF) level and serum immunoglobulin[immunoglobulin A(IgA), immunoglobulin M(IgM), immunoglobulin G(IgG)].Results The total effective rate of treatment in the observation group was 94.87%, higher than 76.92% in the control group, the difference was statistically significant (P <0.05);after treatment, the observation group RF, TNF-α, VEGF, IgA, IgM, IgG were lower than the control group, the difference was statistically significant (P<0.05).Conclusion Iguratimod combined with etanercept can effectively reduce the level of inflammatory factors, improve immunoglobulin and improve the therapeutic effect in patients with refractory rheumatoid arthritis.